doi: 10.3389/fendo.2024.1358404 Received 19 December 2023 Accepted 15 February 2024 Published 05 March 2024 Volume 15 - 2024 Edited by Chen Liu, University of Texas Southwestern Medical Center, United States Reviewed by Surbhi Gahlot, University of Texas Southwestern Medical Center, United States Carlos Manuel Zapata-Martn del Campo, National Institute of Cardiology Ignacio Chavez, Mexico Updates Copyright 2024 Raij and Raij
D1 S2:API Characterization and Sameness Demonstration Format: Presentations and a Panel Discussion with Q&A (Virtual and In-Person Attendees) This session establishes regulatory expectations and scientific approaches for demonstrating API sameness in generic GLP-1 peptide products
11 Induction of the FAK-Paxillin Pathway BPC-157 is thought to phosphorylate focal adhesion kinase (FAK) and paxillin
The evidence base consists primarily of preclinical studies in animal models, with limited clinical data in humans
Zepbound should not be used by anyone who has a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome 2 (MEN2), or pancreatitis
Borzova, V